Trial Profile
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- Acronyms Pride-HD
- Sponsors Prilenia Therapeutics; Teva Pharmaceutical Industries
- 22 Feb 2023 Results of pooled analysis assessing the pridopidine's effect on the QT interval and investigated its cardiac safety profile from NCT02006472, NCT00724048 and NCT00665223 trials, published in the Neurology and Therapy.
- 08 Dec 2020 According to a Prilenia Therapeutics media release, results from this study were published in The Journal of Huntington's Disease.
- 16 Sep 2020 Results of post hoc analysis presented at the 24th International Congress of Parkinson's Disease and Movement Disorders